Welcome to the latest of our Eberhard F. Mammen award announcements. As noted many
times previously, Thieme, the publisher of Seminars in Thrombosis and Hemostasis (STH), has created the “Eberhard F. Mammen Excellence in Thrombosis and Hemostasis Awards ” in honor of Eberhard Mammen ([Fig. 1 ]), and in recognition of his contribution to this field and to the journal that he
both founded and steered for over three decades (see [Table 1 ] for relevant references). These awards began in 2009, under two categories; the
current award details and conditions are as follows:
Table 1
Listing of relevant editorials published in STH as related to the initiation of the
Eberhard F. Mammen awards, as well as previous award announcements
1. Favaloro EJ. Welcome to a special issue of Seminars in Thrombosis and Hemostasis—the
closing issue for 2008. Semin Thromb Hemost 2008;34:693–696
2. Favaloro EJ. A Tribute to Eberhard F. Mammen, M.D. (1930–2008). Semin Thromb Hemost
2008;34:703–708
3. Favaloro EJ. Welcome to the first issue of Seminars in Thrombosis and Hemostasis
for 2009. Semin Thromb Hemost 2009;35:1–2.
4. Favaloro EJ. Winners of the inaugural Eberhard F. Mammen Award for most popular
article. Semin Thromb Hemost 2009;35:587–590
5. Favaloro EJ. 2009 Eberhard F. Mammen Young Investigator Award winners. Semin Thromb
Hemost 2010;36:469–470
6. Favaloro EJ. Winners of the 2010 Eberhard F. Mammen Award for most popular article
during 2008–2009. Semin Thromb Hemost 2010;36(7):685–92.
7. Favaloro EJ. 2011 Eberhard F. Mammen Award announcements. Semin Thromb Hemost 2011;37(5):431–9.
8. Favaloro EJ. 2012 Eberhard F. Mammen Award announcements. Semin Thromb Hemost 2012;38:425–32.
9. Favaloro EJ. 2013 Eberhard F. Mammen Award announcements. Semin Thromb Hemost 2013;39:567–74.
10. Favaloro EJ. 2014 Eberhard F. Mammen award announcements: Part I-most popular
articles. Semin Thromb Hemost 2014;40(4):407–12.
11. Favaloro EJ. 2014 Eberhard F. Mammen Award announcements: Part II - young investigator
awards. Semin Thromb Hemost 2014;40(7):718–23.
12. Favaloro EJ. 2015 Eberhard F. Mammen Award announcements: Part I-most popular
articles. Semin Thromb Hemost 2015;41(7):673–9.
13. Favaloro EJ. 2015 Eberhard F. Mammen Award announcements: Part II-young investigator
awards. Semin Thromb Hemost 2015;41(8):809–15.
14. Favaloro EJ. 2016 Eberhard F. Mammen Award announcements: Part I - most popular
articles. Semin Thromb Hemost 2016;42(4):325–30.
15. Favaloro EJ. 2016 Eberhard F. Mammen Award announcements: Part II-young investigator
awards. Semin Thromb Hemost 2017;43(3):235–241.
16. Favaloro EJ. 2017 Eberhard F. Mammen Award announcements: Part I-most popular
articles. Semin Thromb Hemost 2017;43(4):357–363.
17. Favaloro EJ. 2017 Eberhard F. Mammen Award announcements: Part II- young investigator
awards. Semin Thromb Hemost 2018;44(2):81–88.
18. Favaloro EJ. 2018 Eberhard F. Mammen Award announcements: Part I-most popular
articles. Semin Thromb Hemost 2018;44(3):185–192.
19. Favaloro EJ. 2018 Eberhard F. Mammen Award announcements: Part II-young investigator
awards. Semin Thromb Hemost 2019;45(2):123–129.
20. Favaloro EJ. 2019 Eberhard F. Mammen Award announcements: Part I-most popular
articles. Semin Thromb Hemost 2019;45(3):215–224.
21. Favaloro EJ. 2019 Eberhard F. Mammen Award announcements: Part II—young investigator
awards. Semin Thromb Hemost 2020;46(2):105–113
22. Favaloro EJ. 2020 Eberhard F. Mammen Award announcements: Part I-most popular
articles. Semin Thromb Hemost 2020;46(4):383–392.
Fig. 1 Eberhard F. Mammen (1930–2008).
Most popular article awards: Awarded to the authors of the most popular articles published
in STH. The awards are determined by the Editor in Chief on the basis of user statistics
from Thieme e-journals from the preceding 2 years. Prefaces, errata, letters to the
editor, and editorials, and previous award-winning articles, are excluded from further
consideration of these awards, which currently comprise two categories: one for “Open
Access” articles, and another for a “General Category.” There are two major cash prizes
of US$1,000 for each category. In addition, winners of the “General Category” awards
are granted “open access” status for these articles thereafter.
Young investigator awards: Best presentation or meeting abstract by a young investigator—as
presented or delivered to an international or large regional meeting on a topic related
to the fields of thrombosis and hemostasis—and whose subject matter is determined
to be in the spirit of Dr. Mammen. Up to six cash prizes of US$1,000 are given in
any year. There are some additional considerations and conditions for the award, and
awardees are expected to prepare a review or other papers related to the topic of
their presentation (or as otherwise agreed) for publication in STH. In general, previous
award winners are excluded from a second award to enable more individuals to be recognized.
After nominations are received, the awardees are selected by a vote of the senior
editors of STH. Any potential conflicts of interest are managed by first identifying
these, and then excluding those with potential conflicts from voting. Finally, given
the current COVID-19 pandemic, many international congresses have become virtual meetings,
and accordingly, virtual meeting presentations can also be considered for the award.
Further details of the awards and the award winners are posted online (https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077 ), and previous award winner announcements are also available in print (see [Table 1 ] for a listing of relevant editorials published in this journal as related to the
initiation of the Eberhard F. Mammen awards, as well as previous award announcements;
these publications are also available for free download from the journal Web site:
<https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077 >).
The winners of the 2020 Eberhard F. Mammen awards for the most popular articles from
STH for the period of 2018 to 2019 inclusive were announced in an earlier issue of
the journal.[1 ] It is therefore with great pleasure that we would like to announce the winners of
the latest round of Young Investigator Awards.
As mentioned above, the Young Investigator Awards represent winners of the best presentation
or meeting abstract by a young investigator—as presented or delivered to an international
or large regional meeting (virtual meetings permissible) on a topic related to the
fields of thrombosis and hemostasis—and whose subject matter is determined to be in
the spirit of Dr. Mammen. There are additional considerations given that the nominees'
presentations are not always seen by all of the possible award nominators, being drawn
from the editorial team of the journal. The latest winners are identified below and
also in [Table 2 ], with a running list of previous awardees, and the resulting publications in the
journal, given in [Table 3 ]. The latest awardees were derived from a variety of meetings, including the latest
meetings of the International Society on Thrombosis and Haemostasis (ISTH) and the
American Society of Hematology. All meetings were held virtually.
Table 2
Latest (2020) Eberhard F. Mammen Young Investigator Award winners
Awardee
Current affiliation(s)
Presentation(s) awarded
Proposed submission to STH
Hanny Al-Samkari
Division of Hematology/Oncology, Hereditary Hemorrhagic Telangiectasia Center, Massachusetts
General Hospital, Harvard Medical School, United States
ISTH2020 (https://www.isth2020.org/ ). Presentation: Thrombosis, bleeding, and the effect of anticoagulation on survival
in critically ill patients with COVID-19 in the United States.
Systemic angiogenic inhibition to treat bleeding in hereditary hemorrhagic telangiectasia
Matthias M Engelen
Center for Molecular and Vascular Biology, Department of Cardiovascular Diseases,
University Hospitals (UZ) Leuven, Leuven, Belgium
ISTH2020 (https://www.isth2020.org/ ). Presentation: Incidence of venous thromboembolism in patients discharged after
COVID-19 hospitalization.
Venous thromboembolism in patients discharged after COVID-19 hospitalization
Imre Varju, Hungary
Semmelweis University, Budapest, Hungary
ISTH2020 (https://www.isth2020.org/ ). Presentation: Fibrinogen is citrullinated in venous thrombi and forms fragile clots
with increased resistance to lysis
NETs at the crossroad of antithrombosis and thrombolysis
Ellen Driever
University Medical Center Groningen, the Netherlands
International Liver Congress (ILC 2020) (https://ilc-congress.eu/programme-digital-ilc-2020/ ). Presentation: The VWF/ADAMTS13 imbalance, but not global coagulation or fibrinolysis,
is associated with outcome and bleeding in patients with acute liver failure
Coagulation and inflammation in critically ill liver patients.
Christine Lee
Platelet and Thrombosis Research Laboratory, The ANZAC Research Institute, Concord
Repatriation General Hospital, NSW Australia
Faculty of Medicine and Health, University of Sydney, Sydney, NSW Australia
ASH2020 (https://ash.confex.com/ash/2020/webprogram/start.html ). Presentation: Soluble platelet agonists expand the procoagulant surface in heparin-induced
thrombocytopenia.
Procoagulant platelets in thrombotic conditions
Maria Selvadurai
Australian Centre for Blood Diseases, Monash University, Victoria, Australia
ASH2020 (https://ash.confex.com/ash/2020/webprogram/start.html ). Presentation: Soluble platelet agonists expand the procoagulant surface in heparin-induced
thrombocytopenia.
Mechanisms of thrombosis in HIT: an update
Table 3
Eberhard F. Mammen Young Investigator Award winners from previous years
Awardee
Year awarded
Publication arising
Willem M. Lijfering
2009
Lijfering WM, Flinterman LE, Vandenbroucke JP, Rosendaal FR, Cannegieter SC. Relationship
between venous and arterial thrombosis: a review of the literature from a causal perspective.
Semin Thromb Hemost 2011 Nov;37(8):885–96.
Salley Pels
2009
Pels SG. Current therapies in primary immune thrombocytopenia. Semin Thromb Hemost
2011 Sep;37(6):621–30.
Adam Cuker
2010
Cuker A. Current and emerging therapeutics for heparin-induced thrombocytopenia. Semin
Thromb Hemost 2012 Feb;38(1):31–7.
Giridhara Rao Jayandharan
2010
Jayandharan GR, Srivastava A, Srivastava A. Role of molecular genetics in hemophilia:
from diagnosis to therapy. Semin Thromb Hemost 2012 Feb;38(1):64–78.
Timea Szanto
2010
Szántó T, Joutsi-Korhonen L, Deckmyn H, Lassila R. New insights into von Willebrand
disease and platelet function. Semin Thromb Hemost 2012 Feb;38(1):55–63.
Birgitta Salmela
2010
Salmela B, Joutsi-Korhonen L, Armstrong E, Lassila R. Active online assessment of
patients using new oral anticoagulants: bleeding risk, compliance, and coagulation
analysis. Semin Thromb Hemost 2012 Feb;38(1):23–30.
Pia Riittaa-Maria Siljander
2010
Aatonen M, Grönholm M, Siljander PR. Platelet-derived microvesicles: multitalented
participants in intercellular communication. Semin Thromb Hemost 2012 Feb;38(1):102–13.
Romaric Lacroix
2011
Lacroix R, Dignat-George F. Microparticles: new protagonists in pericellular and intravascular
proteolysis. Semin Thromb Hemost 2013 Feb;39(1):33–9.
Brad McEwen
2011
McEwen BJ, Morel-Kopp MC, Chen W, Tofler GH, Ward CM. Effects of omega-3 polyunsaturated
fatty acids on platelet function in healthy subjects and subjects with cardiovascular
disease. Semin Thromb Hemost 2013 Feb;39(1):25–32.
Neil A. Goldenberg
2011
Bernard TJ, Armstrong-Wells J, Goldenberg NA. The institution-based prospective inception
cohort study: design, implementation, and quality assurance in pediatric thrombosis
and stroke research. Semin Thromb Hemost 2013 Feb;39(1):10–4.
Vivien Chen
2011
Chen VM. Tissue factor de-encryption, thrombus formation, and thiol-disulfide exchange.
Semin Thromb Hemost 2013 Feb;39(1):40–7.
Joseph E. Italiano, Jr.
2011
Italiano JE Jr. Unraveling mechanisms that control platelet production. Semin Thromb
Hemost 2013 Feb;39(1):15–24.
Vivian Xiaoyan Du
2012/2013
Du VX, Huskens D, Maas C, Al Dieri R, de Groot PG, de Laat B. New insights into the
role of erythrocytes in thrombus formation. Semin Thromb Hemost 2014 Feb;40(1):72–80.
Andrew Yee
2012/2013
Yee A, Kretz CA. Von Willebrand factor: form for function. Semin Thromb Hemost 2014
Feb;40(1):17–27.
Sarah O'Brien
2012/2013
O'Brien SH. Contraception-related venous thromboembolism in adolescents. Semin Thromb
Hemost 2014 Feb;40(1):66–71.
Veronica Flood
2012/2013
Flood VH. Perils, problems, and progress in laboratory diagnosis of von Willebrand
disease. Semin Thromb Hemost 2014 Feb;40(1):41–8.
Julie Tange
2012/2013
Tange JI, Grill D, Koch CD, Ybabez RJ, Krekelberg BJ, Fylling KA, Wiese CR, Baumann
NA, Block DR, Karon BS, Chen D, Pruthi RK. Local verification and assignment of mean
normal prothrombin time and international sensitivity index values across various
instruments: recent experience and outcome from North America. Semin Thromb Hemost
2014 Feb;40(1):115–20.
Kent Chapman
2012/2013
Chapman K, Yuen S. Therapy for thrombotic thrombocytopenia purpura: past, present,
and future. Semin Thromb Hemost 2014 Feb;40(1):34–40.
Andreas Tiede
2014
Tiede A, Werwitzke S, Scharf RE. Laboratory diagnosis of acquired hemophilia a: limitations,
consequences, and challenges. Semin Thromb Hemost 2014 Oct;40(7):803–11
Wendy Lim
2014
Lim W. Thrombotic risk in the antiphospholipid syndrome. Semin Thromb Hemost 2014
Oct;40(7):741–6.
Susana Nobre Fernandes
2014
Fernandes S, Carvalho M, Lopes M, Araújo F. Impact of an individualized prophylaxis
approach on young adults with severe hemophilia. Semin Thromb Hemost 2014 Oct;40(7):785–9.
Maria Elisa Mancuso
2014
Mancuso ME, Fasulo MR. Thrombin generation assay as a laboratory monitoring tool during
by-passing therapy in patients with hemophilia and inhibitors. Semin Thromb Hemost
2016 Feb;42(1):30–5.
Coen Maas
2014
Tersteeg C, Fijnheer R, Deforche L, Pasterkamp G, de Groot PG, Vanhoorelbeke K, de
Maat S, Maas C. Keeping von Willebrand factor under control: alternatives for ADAMTS13.
Semin Thromb Hemost 2016 Feb;42(1):9–17.
Riten Kumar
2014
Kumar R, Dunn A, Carcao M. Changing Paradigm of hemophilia management: extended half-life
factor concentrates and gene therapy. Semin Thromb Hemost 2016 Feb;42(1):18–29.
Juraj Sokol
2015
Sokol J, Skerenova M, Jedinakova Z, Simurda T, Skornova I, Stasko J, Kubisz P. Progress
in the understanding of sticky platelet syndrome. Semin Thromb Hemost 2017;43(1):8–13
Ljubica Jovanović
2015
Jovanovic L, Antonijevic N, Novakovic T, Savic N, Terzic B, Zivkovic I, Radovanovic
N, Asanin M. Practical aspects of monitoring of antiplatelet therapy. Semin Thromb
Hemost 2017;43(1):14–23
Lucia Stanciakova
2015
Stanciakova L, Dobrotova M, Jedinakova Z, Duraj L, Skornova I, Korinkova L, Holly
P, Danko J, Stasko J, Kubisz P. Monitoring of hemostasis and management of anticoagulant
thromboprophylaxis in pregnant women with increased risk of fetal loss. Semin Thromb
Hemost 2016 Sep;42(6):612–21.
Tina Biss
2015
Biss TT. Venous thromboembolism in children: is it preventable? Semin Thromb Hemost
2016 Sep;42(6):603–11.
Tobias Fuchs
2015
Jiménez-Alcázar M, Kim N, Fuchs TA. Circulating extracellular DNA: cause or consequence
of thrombosis? Semin Thromb Hemost 2017 Sep;43(6):553–561
Jonathan M. Coutinho
2015
Silvis SM, Middeldorp S, Zuurbier SM, Cannegieter SC, Coutinho JM. Risk factors for
cerebral venous thrombosis. Semin Thromb Hemost 2016 Sep;42(6):622–31.
Soundarya Selvam
2016
Selvam S, James P. Angiodysplasia in von Willebrand disease: understanding the clinical
and basic science. Semin Thromb Hemost 2017 Sep;43(6):572–580.
Vincent Muczynski
2016
Muczynski V, Christophe OD, Denis CV, Lenting PJ. Emerging therapeutic strategies
in the treatment of hemophilia A. Semin Thromb Hemost 2017 Sep;43(6):581–590.
Karen Schreiber
2016
Schreiber K, Breen K, Cohen H, Jacobsen S, Middeldorp S, Pavord S, Regan L, Roccatello
D, Robinson SE, Sciascia S, Seed PT, Watkins L, Hunt BJ. HYdroxychloroquine to Improve
Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) Protocol: a
multinational randomized controlled trial of hydroxychloroquine versus placebo in
addition to standard treatment in pregnant women with antiphospholipid syndrome or
antibodies. Semin Thromb Hemost 2017 Sep;43(6):562–571.
Jasmine Wee Ting Tay
2016
Tay J, Tiao J, Hughes Q, Jorritsma J, Gilmore G, Baker R. Circulating microRNA as
thrombosis sentinels: caveats and considerations. Semin Thromb Hemost 2018 Apr;44(3):206–215.
Adi J. Klil-Drori
2016
Klil-Drori AJ, Tagalakis V. Direct oral anticoagulants in end-stage renal disease.
Semin Thromb Hemost 2018 Jun;44(4):353–363.
Lindsey A. George
2016
Submission pending.
Ivar van Asten
2017
van Asten I, Schutgens REG, Urbanus RT. Toward Flow Cytometry based platelet function
diagnostics. Semin Thromb Hemost 2018 Apr;44(3):197–205.
Elodie Laridan
2017
Laridan E, Martinod K, De Meyer SF. Neutrophil extracellular traps in arterial and
venous thrombosis. Semin Thromb Hemost 2019 Feb;45(1):86–93.
Leonardo Pasalic
2017
Blennerhassett R, Curnow J, Pasalic L. Immune-mediated thrombotic thrombocytopenic
purpura: a narrative review of diagnosis and treatment in adults. Semin Thromb Hemost
2020 Apr;46(3):289–301
Yvonne Brennan
2017
Brennan Y, Favaloro EJ, Curnow J. To maintain or cease non-vitamin K antagonist oral
anticoagulants prior to minimal bleeding risk procedures: a review of evidence and
recommendations. Semin Thromb Hemost 2019
Mar;45(2):171–179.
Georgia McCaughan
2017
Submission pending.
Mark Schreuder, MSc
2018
Schreuder M, Reitsma PH, Bos MHA. Reversal Agents for the Direct Factor Xa inhibitors:
biochemical mechanisms of current and newly emerging therapies. Semin Thromb Hemost
2020 Nov;46(8):986–998
James McFadyen MBBS FRACP PhD
2018
Stevens H, McFadyen JD. Platelets as central actors in thrombosis-reprising an old
role and defining a new character. Semin Thromb Hemost 2019 Nov;45(8):802–809.
David Rabbolini BSc MBBCh (Witw.), FRACP FRCPA PhD
2018
Mason AG, Rabbolini DJ. The current role of platelet function testing in clinical
practice. Semin Thromb Hemost, in press.
Janka Zolkova, MSc
2018
Zolkova J, Sokol J, Simurda T, Vadelova L, Snahnicanova Z, Loderer D, Dobrotova M,
Ivankova J, Skornova I, Lasabova Z, Kubisz P, Stasko J. Genetic background of von
Willebrand disease: history, current state and future perspectives. Semin Thromb Hemost
2020 Jun;46(4):484–500
Tomáš Bolek MD
2018
Bolek T, Samoš M, Škorňová I, Galajda P, Staško J, Kubisz P, Mokáň M. Proton pump
inhibitors and dabigatran therapy: impact on gastric bleeding and dabigatran plasma
levels. Semin Thromb Hemost 2019 Nov;45(8):846–850.
Fraser McCrae BSc (Hons)
2018
Submission pending.
Elisa Danese
2019
Danese E, Montagnana M, Gelati M, Lippi G. The role of epigenetics in the regulation
of hemostatic balance. Semin Thromb Hemost 2021 Feb;47(1):53–62.
Soracha Ward
2019
Ward S, O'Sullivan JM, O'Donnell JS. The biological significance of von Willebrand
factor O linked glycosylation. Semin Thromb Hemost 2021, in press.
Jonathan Douxfils
2019
Douxfils J, Morimont L, Bouvy C. Oral contraceptives and venous thromboembolism: focus
on testing that may enable prediction and assessment of the risk. Semin Thromb Hemost
2020 Nov;46(8):872–886.
Erik Klok
2019
Boon GJAM, Huisman MV, Klok FA. Why, whom, and how to screen for chronic thromboembolic
pulmonary hypertension after acute pulmonary embolism. Semin Thromb Hemost 2020 Dec
21. (e-pub ahead of print). doi:10.1055/s-0040-1718925. PMID: 33348411.
Michelle Lavin
2019
Byrne B, Ryan K, Lavin M. Current challenges in the peripartum management of women
with von Willebrand Disease. Semin Thromb Hemost 2021, in press.
Deeksha Khialani
2019
Khialani D, Rosendaal F, Vlieg AVH. Hormonal contraceptives and the risk of venous
thrombosis. Semin Thromb Hemost 2020 Nov;46(8):865–871.
As often occurs with these awards, the current crop of winners reflects a variety
of “Young Investigators” at various stages of their careers. Some awardees are just
starting out on their journey in science or medicine, while others are better established
in their careers and crossing over into the next phase of their life where they will
soon no longer be called “young” investigators.
Hanny Al-Samkari ([Fig. 2 ]) is an Instructor in Medicine at Harvard Medical School and a clinical investigator
in the Massachusetts General Hospital (MGH) Division of Hematology, where he focuses
on bleeding disorders and rare hematologic diseases. He also serves as the Associate
Director of the MGH Hereditary Hemorrhagic Telangiectasia (HHT) Center of Excellence.
His clinical and research focuses include several areas within hemostasis, including
systemic therapies for bleeding in HHT, thrombopoietic growth factors in various thrombocytopenias,
and various topics in diagnosis and treatment of immune thrombocytopenia. He currently
serves as principle investigator for several clinical trials in these areas. From
the start of the COVID-19 pandemic, he has also been very active in investigation
of bleeding, thrombosis, and anticoagulation in patients with COVID-19. He has published
over 70 articles in peer-reviewed journals, serves on several national and international
committees including the working group for the Second International HHT Guidelines,
and is the Hematology Associate Editor for the Orphanet Journal of Rare Diseases.
Fig. 2 Young Investigator Award winner Hanny Al-Samkari.
Matthias Engelen ([Fig. 3 ]) is a PhD candidate at the University of Leuven. After he graduated as a medical
doctor in 2017, he trained in internal medicine as a junior doctor at the University
Hospitals Leuven. His master's dissertation investigated the clinical use of thrombolytic
therapy. Last year, he started working on contact activation in cardiovascular diseases
as a PhD researcher at the University of Leuven, under the supervision of Prof. Dr.
Thomas Vanassche, Prof. Dr. Christophe Vandenbriele, and Prof. Dr. Peter Verhamme.
His project was awarded with best project by the Belgian Society of Thrombosis and
Hemostasis in 2019, and has so far resulted in several abstracts and a late-breaking
presentation at international congresses.
Fig. 3 Young Investigator Award winner Matthias Engelen.
Imre Varju ([Fig. 4 ]) is a Fulbright Scholar in medical science and a Health Communication Specialist
with over 10 years of experience in the field of hemostasis, with a special focus
on the impact of neutrophil extracellular traps on thrombus formation and dissolution.
He obtained his MD and PhD at Semmelweis University, Hungary, completed postdoctoral
trainings at the Hungarian Academy of Sciences, the National Institute for Biological
Standards for Control, United Kingdom, and at Harvard Medical School, and obtained
his MPH at Columbia University. He is a Senior Lecturer at Semmelweis University and
holds a Manager, Learning Strategy position at FCB Health New York.
Fig. 4 Young Investigator Award winner Imre Varju.
Ellen Driever ([Fig. 5 ]) is a PhD candidate from the University Medical Center Groningen, the Netherlands.
Her research is about thrombosis and hemostasis in patients with liver diseases, with
a focus on the pathogenesis and treatment of portal vein thrombosis in cirrhotic patients.
She studied Pharmacy in Groningen (the Netherlands), and also completed a research
project at the Department of Biological Engineering at the Massachusetts Institute
of Technology (Boston, MA).
Fig. 5 Young Investigator Award winner Ellen Driever.
Christine Lee ([Fig. 6 ]) is a first-year postdoctoral researcher under the supervision of Associate Professor
Vivien Chen at the ANZAC Research Institute and University of Sydney. She is passionate
in undertaking studies with clear translational potential and developing assays that
will impact on the clinical outcomes of patients. In 2019, she completed her PhD under
the supervision of Professor Elizabeth Gardiner and Dr. Philip Choi at the John Curtin
School of Medical Research, the Australian National University. Her PhD thesis investigated
the shedding mechanism of the major platelet collagen receptor, glycoprotein VI, in
healthy donors and in patients with heparin-induced thrombocytopenia.
Fig. 6 Young Investigator Award winner Christine Lee.
Maria Selvadurai ([Fig. 7 ]) is a recent MD-PhD graduate from Monash University and a junior doctor at Alfred
Health. She undertook her final year MD research project on soluble platelet agonists
in heparin-induced thrombocytopenia at the ANZAC Research Institute, Sydney, under
the supervision of Dr. Vivien Chen and Dr. Christine Lee. Her PhD, completed in 2019,
examined the cellular effects of class II PI3Ks in platelets, and the biological implications
of targeting these pharmacologically as a novel antithrombotic strategy, and was supervised
by A/Prof. Justin Hamilton and Prof. Harshal Nandurkar at the Australian Centre for
Blood Diseases, Monash University.
Fig. 7 Young Investigator Award winner Maria Selvadurai.
All award winners were elated to hear that they had been selected to receive an Eberhard
F. Mammen Young Investigator award, and provided the following additional commentary.
“I am deeply honored and privileged to have been nominated and selected for an Eberhard
F. Mammen Young Investigator Award. Dr. Mammen was a luminary in our field, and it
is particularly meaningful for me as a hemostasis investigator to receive an award
in his honor. I would like to thank my many research collaborators and mentors, without
whom my work would not have been possible. I would also like to thank Dr. Favaloro
and the editorial team of Seminars in Thrombosis and Hemostasis for their recognition of our work. The future of hemostasis research has never been
more promising, and together with my colleagues I am certain we will advance the care
of patients with hereditary hemorrhagic telangiectasia, thrombocytopenias, and many
other bleeding and thrombotic disorders.”
- Hanny Al-Samkari ([Fig. 2 ])
“I am very grateful and honored to be awarded an Eberhard F. Mammen Young Investigator
Award for our research on venous thromboembolism in patients discharged after COVID-19
hospitalization, as presented at the ISTH meeting in July 2020 (abstract number LB/CO01.3).
I would like to thank the Editor in Chief, Dr. Favaloro, and the editorial board of
Seminars in Thrombosis and Hemostasis for this wonderful recognition. As this research was very much a team effort, I would
like to thank my supervisors Prof. Vanassche, Vandenbriele, and Verhamme for their
excellent mentorship in these challenging times and the Department of Cardiovascular
Diseases—particularly the Vascular Center—for making this research possible.”
- Matthias Engelen ([Fig. 3 ])
“I am beyond honored to have received an Eberhard F. Mammen Young Investigator Award.
To me, this recognition has special value in an era that demonstrates how clear communication
of science is just as important as science itself. To my science family: Dr. Krasimir
Kolev's lab at Semmelweis, Dr. Colin Longstaff's lab at NIBSC, and Dr. Denisa Wagner's
lab at Harvard—thank you for your mentorship and collaboration. To my Public Health
and Health Communication families at Columbia University, FCB Health and beyond: thank
you for your continuous support. Finally, to the selection committee: thank you for
your consideration and this humbling recognition.”
- Imre Varju ([Fig. 4 ])
“I am honored to be awarded an Eberhard F. Mammen Young Investigator Award. I very
much appreciate the recognition for my work on the association between bleeding or
outcome and the hemostatic state in patients with acute liver failure. This award
acknowledges a team effort, and this achievement would not have been possible without
the support of the entire team, in particular my supervisor Professor Ton Lisman.
This award will thrive my future research efforts.”
- Ellen Driever ([Fig. 5 ])
“I am humbled and honored to receive an Eberhard F. Mammen Young Investigator Award
for our work on procoagulant platelets in heparin-induced thrombocytopenia. This award
is a testament to the invaluable support and mentorship I received from my supervisors
and mentors, Associate Professor Vivien Chen, and Professor Elizabeth Gardiner, and
is a recognition of the team effort by my coauthors and colleagues. As a first-year
postdoctoral researcher, this award spurs me on to continue my contribution in this
field.”
- Christine Lee ([Fig. 6 ])
“It is an honor to be awarded a 2020 Eberhard F. Mammen Young Investigator Award together
with my colleague Dr. Christine Lee. I have been inspired by a number of previous
winners of this award, and it is a huge privilege to follow in their footsteps. I
would like to thank the editorial team of Seminars in Thrombosis and Haemostasis for selecting our presentation for this award, and Dr. Emmanuel Favaloro for delivering
the good news. I am also extremely grateful to Dr. Vivien Chen and Dr. Lee for the
fantastic opportunity to work on this project with them, and for their wonderful support
and mentorship. Finally, I would like to thank the past and present members of the
Platelet and Thrombosis Laboratory at the ANZAC Research Institute, without whose
important contributions over many years this project would not have been possible.”
- Maria Selvadurai ([Fig. 7 ])
In keeping with previous editorials, I have again reviewed the Young Investigator
awardees from previous years as well as the outcome of their subsequent submissions
to STH, as summarized in [Table 3 ]. The most recent contributions are also listed in the reference list.[2 ]
[3 ]
[4 ]
[5 ]
[6 ]
[7 ]
[8 ]
[9 ]
[10 ]
[11 ]
[12 ]
[13 ]
[14 ]
[15 ] I previously mentioned my personal gratification that most of the papers from earlier
years have subsequently appeared in several annual top 100 listings. Of further interest,
some of these papers or the young investigators themselves have subsequently won one
of the most popular awards. It is also motivating to observe that several of the Young
Investigator awardees were coauthors on other contributions to STH that were also
listed in these most popular listings.
I look forward to seeing the careers of the current and past Young Investigator Award
winners to continue to develop. The above also infers that very high bars are now
established for future Young Investigator awardees, and I wish all awardees the best
of luck to exceed the precedence set by earlier award winners.
